Shift Bioscience

📍 Cambridge, United Kingdom🗓 Founded 2017👥 24 employees💰 Last funded Jun 2024
Biotechnology Research🌐 shiftbioscience.com
Website LinkedIn
Shift Bioscience is a biotech company uncovering the biology of cell rejuvenation to develop new therapies for age-driven diseases. Cell aging is the primary, underlying driver for many of today’s major diseases, but is yet to be truly leveraged as a therapeutic target. Operating at the intersection of machine learning and cell biology, Shift’s narrow-AI approach leverages large-scale, proprietary multiomic datasets to uncover the hidden biology of cell aging and rejuvenation. Through this, the Company has built a robust pipeline of rejuvenation targets, including SB000 – a novel, single-gene target capable of cell rejuvenation across multiple cell types. Shift Bioscience was founded in 2017 by Dr Daniel Ives, CEO, and Dr Brendan Swain, CSO. The Company is based at the Gurdon Institute, Cambridge thanks to the Frame Shift bio-incubator, an initiative of the Milner Therapeutics Institute, and has additional computational facilities in Toronto, Canada.
2
Total investors
0
Early stage
0
Mid stage
2
Late stage
2017
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
2
Frequently asked questions
Who invested in Shift Bioscience?
Shift Bioscience has 2 investors on record on gritt.io and 2 late-stage investors.
When did Shift Bioscience last raise funding?
The most recent investment in Shift Bioscience recorded on gritt.io was in June 2024.
When was Shift Bioscience founded?
Shift Bioscience was founded in 2017.
What industry is Shift Bioscience in?
Shift Bioscience operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Shift Bioscience based?
Shift Bioscience is headquartered in Cambridge, United Kingdom.